Azienda Sanitaria Locale 5 Spezzino
- Address
- lock Available on a paid plan
Medical Oncology Research at Azienda Sanitaria Locale 5 Spezzino
Clinical research here focuses on neoplasms, especially metastatic colorectal cancer, with studies designed to compare first-line treatment approaches and better define which therapy offers the most effective disease control for patients starting systemic care.
- Evaluation of bevacizumab and chemotherapy versus cetuximab and chemotherapy for treatment effectiveness in advanced colorectal cancer
- Focus on RAS/BRAF findings to support more precise treatment selection
- Improving outcomes for patients who have not yet received therapy for advanced or metastatic disease
The work at this hospital-based site in La Spezia centers on refining cancer treatment choices and supporting more personalized care for people with mCRC.
Cardiovascular Diseases and Diabetes-Related Prevention Studies
This research area addresses cardiovascular diseases in type 2 diabetes, with trials aimed at lowering the risk of serious heart and vascular events in patients who have not yet experienced prior cardiovascular complications.
- Testing colchicine and aspirin for prevention of major cardiovascular events
- Studying whether adding these therapies to standard care can improve long-term outcomes in high-risk diabetes
- Evaluating both safety and effectiveness in people with diabetes but no evident cardiovascular disease
These studies reflect a preventive approach, aiming to reduce future complications and improve everyday health outcomes for patients managed at Azienda Sanitaria Locale 5 Spezzino.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale 5 Spezzino
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-11-21 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.